On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- Patients now shop for doctors like consumers, and the bar just got higher (Medical Economics)
- AI in GI cancer care: From recognition to clinical value (ESMO)
- Could the Gut Microbiome Improve Colorectal Cancer Screening? (Technology Networks)
- DDW Expert Picks: Endoscopists’ Peripheral Gaze, Antibiotics for Cholangitis, and More (GI & Endoscopy News)
- The loopholes PE built to buy physicians are starting to crack (Becker’s Healthcare)
- Barrett Esophagus May Strike Decades Before Official Diagnosis (Medscape)
- A blood-based test for detection of advanced adenomas and colorectal cancer (DENEB): a multicentre diagnostic accuracy study (The Lancet Gastroenterology & Hepatology)
- AI can analyze your poop. Should it? (Business Insider)
